Neuron23 Appoints Andrew Yost, MBA, as Chief Business Officer
Senior industry leader brings substantial strategy, business development, and operations experience SOUTH SAN FRANCISCO, Calif. – August 22, 2023 – Neuron23™ Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the appointment of Andrew Yost, MBA, as the company’s chief business officer (CBO). Mr. Yost […]